Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
J Clin Virol ; 155: 105267, 2022 10.
Article in English | MEDLINE | ID: mdl-36007460

ABSTRACT

BACKGROUND: We investigated Epstein-Barr virus (EBV) antibody kinetics in university freshmen who developed laboratory-documented primary EBV infection during prospective studies and correlated these kinetics with disease severity. METHODS: EBV-naïve participants had blood collected periodically and sera tested for EBV-specific antibodies with line blot and enzyme immunoassays. The line blot assay contained EBNA-1, p18, p23, BZLF-1, p138, and p54 antigens; the enzyme immunoassay contained viral capsid antigen and EBNA-1. Severity of illness (SOI) was graded 0 (asymptomatic) to 6 (bedridden). Participants with maximum SOI scores 0-2 were compared with those whose maximum SOI scores were 3-6. Time to first antibody response was analyzed using the semi-parametric COX model. RESULTS: A total of 201 sera from 38 college students collected before, during, and after primary EBV infection were tested. Earlier antibody responses correlated with milder symptoms. This was most pronounced for late-developing antibodies. The median time to development of p18 IgG was significantly earlier among low-SOI participants (64 days) than high-SOI patients (119 days; P = 0.0003).). Participants with mild disease developed EBNA-1 antibodies sooner than participants with more severe disease (125 days versus >270 days; P = 0.017). Participants with mild disease also showed more rapid loss of antibodies against IgG EA p138 and p54 ≥12 weeks post-infection (P = 0.012 and P = 0.026, respectively). CONCLUSIONS: These data suggest that rapid antibody responses to EBV correlate with reduced severity of primary EBV infection.


Subject(s)
Epstein-Barr Virus Infections , Herpesvirus 4, Human , Antibodies, Viral , Antibody Formation , Antigens, Viral , Epstein-Barr Virus Infections/diagnosis , Humans , Immunoglobulin G , Prospective Studies
3.
Hum Gene Ther ; 33(7-8): 432-441, 2022 04.
Article in English | MEDLINE | ID: mdl-35156839

ABSTRACT

Adeno-associated virus (AAV)-mediated gene therapy may provide durable protection from bleeding events and reduce treatment burden for people with hemophilia A (HA). However, pre-existing immunity against AAV may limit transduction efficiency and hence treatment success. Global data on the prevalence of AAV serotypes are limited. In this global, prospective, noninterventional study, we determined the prevalence of pre-existing immunity against AAV2, AAV5, AAV6, AAV8, and AAVrh10 among people ≥12 years of age with HA and residual FVIII levels ≤2 IU/dL. Antibodies against each serotype were detected using validated, electrochemiluminescent-based enzyme-linked immunosorbent assays. To evaluate changes in antibody titers over time, 20% of participants were retested at 3 and 6 months. In total, 546 participants with HA were enrolled at 19 sites in 9 countries. Mean (standard deviation) age at enrollment was 36.0 (14.87) years, including 12.5% younger than 18 years, and 20.0% 50 years of age and older. On day 1, global seroprevalence was 58.5% for AAV2, 34.8% for AAV5, 48.7% for AAV6, 45.6% for AAV8, and 46.0% for AAVrh10. Considerable geographic variability was observed in the prevalence of pre-existing antibodies against each serotype, but AAV5 consistently had the lowest seroprevalence across the countries studied. AAV5 seropositivity rates were 51.8% in South Africa (n = 56), 46.2% in Russia (n = 91), 40% in Italy (n = 20), 37.2% in France (n = 86), 26.8% in the United States (n = 71), 26.9% in Brazil (n = 26), 28.1% in Germany (n = 89), 29.8% in Japan (n = 84), and 5.9% in the United Kingdom (n = 17). For all serotypes, seropositivity tended to increase with age. Serostatus and antibody titer were generally stable over the 6-month sampling period. As clinical trials of AAV-mediated gene therapies progress, data on the natural prevalence of antibodies against various AAV serotypes may become increasingly important.


Subject(s)
Dependovirus , Hemophilia A , Antibodies, Neutralizing , Antibodies, Viral , Dependovirus/genetics , Genetic Vectors/genetics , Hemophilia A/epidemiology , Hemophilia A/genetics , Hemophilia A/therapy , Humans , Prospective Studies , Seroepidemiologic Studies , Serogroup
4.
Mol Ther ; 29(2): 597-610, 2021 02 03.
Article in English | MEDLINE | ID: mdl-33309883

ABSTRACT

Evaluation of immune responses to adeno-associated virus (AAV)-mediated gene therapies prior to and following dose administration plays a key role in determining therapeutic safety and efficacy. This report describes up to 3 years of immunogenicity data following administration of valoctocogene roxaparvovec (BMN 270), an AAV5-mediated gene therapy encoding human B domain-deleted FVIII (hFVIII-SQ) in a phase 1/2 clinical study of adult males with severe hemophilia A. Patients with pre-existing humoral immunity to AAV5 or with a history of FVIII inhibitors were excluded from the trial. Blood plasma and peripheral blood mononuclear cell (PBMC) samples were collected at regular intervals following dose administration for assessment of humoral and cellular immune responses to both the AAV5 vector and transgene-expressed hFVIII-SQ. The predominant immune response elicited by BMN 270 administration was largely limited to the development of antibodies against the AAV5 capsid that were cross-reactive with other common AAV serotypes. No FVIII inhibitor responses were observed within 3 years following dose administration. In a context of prophylactic or on-demand corticosteroid immunosuppression given after vector infusion, AAV5 and hFVIII-SQ peptide-specific cellular immune responses were intermittently detected by an interferon (IFN)-γ and tumor necrosis factor (TNF)-α FluoroSpot assay, but they were not clearly associated with detrimental safety events or changes in efficacy measures.


Subject(s)
Dependovirus/genetics , Genetic Therapy , Genetic Vectors/genetics , Hemophilia A/genetics , Hemophilia A/therapy , Adult , Cross Reactions/immunology , Dependovirus/immunology , Factor VIII/genetics , Genetic Therapy/adverse effects , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Genetic Vectors/adverse effects , Host Microbial Interactions/immunology , Humans , Immunity, Humoral , Male , Transgenes , Treatment Outcome
5.
Mediterr J Hematol Infect Dis ; 12(1): e2020016, 2020.
Article in English | MEDLINE | ID: mdl-32180911

ABSTRACT

No licensed vaccine is available for prevention of EBV-associated diseases, and robust, high-throughput bioanalytical assays are needed to evaluate immunogenicity of gp350 subunit-based candidate EBV vaccines. Here we have developed an improved EBV-GFP based neutralization assay for such a vaccine's pre-clinical and clinical validation to measure EBV specific neutralizing antibodies in human donors. The supplementation of guinea pig complement of our previously published high-throughput EBV-GFP fluorescent focus (FFA)-based neutralization assay allowed the detection of complement-dependent neutralizing antibodies using a panel of heat-inactivated healthy human sera. Anti-gp350 antibody titers, which were evaluated using a previously optimized anti-gp350 IgG ELISA assay, were moderately correlated to the FFA-based neutralization titers. Overall, this improved high-throughput neutralization assay is capable of characterizing the serologic neutralizing antibody response to natural EBV infection, with applications in evaluating EBV antibody status in epidemiologic studies and immunogenicity of candidate gp350-subunit EBV vaccines in clinical studies.

6.
Mol Ther Methods Clin Dev ; 13: 440-452, 2019 Jun 14.
Article in English | MEDLINE | ID: mdl-31193016

ABSTRACT

Adeno-associated virus (AAV)-based vectors are widely used for gene therapy, but the effect of pre-existing antibodies resulting from exposure to wild-type AAV is unclear. In addition, other poorly defined plasma factors could inhibit AAV vector transduction where antibodies are not detected. To better define the relationship between various forms of pre-existing AAV immunity and gene transfer, we studied valoctocogene roxaparvovec (BMN 270) in cynomolgus monkeys with varying pre-dose levels of neutralizing anti-AAV antibodies and non-antibody transduction inhibitors. BMN 270 is an AAV5-based vector for treating hemophilia A that encodes human B domain-deleted factor VIII (FVIII-SQ). After infusion of BMN 270 (6.0 × 1013 vg/kg) into animals with pre-existing anti-AAV5 antibodies, there was a mean decrease in maximal FVIII-SQ plasma concentration (Cmax) and AUC of 74.8% and 66.9%, respectively, compared with non-immune control animals, and vector genomes in the liver were reduced. In contrast, animals with only non-antibody transduction inhibitors showed FVIII-SQ plasma concentrations and liver vector copies comparable with those of controls. These results demonstrate that animals without AAV5 antibodies are likely responders to AAV5 gene therapy, regardless of other inhibiting plasma factors. The biological threshold for tolerable AAV5 antibody levels varied between individual animals and should be evaluated further in clinical studies.

7.
Res Pract Thromb Haemost ; 3(2): 261-267, 2019 Apr.
Article in English | MEDLINE | ID: mdl-31011710

ABSTRACT

BACKGROUND: Current treatment for severe hemophilia A is replacement of deficient factor. Although replacement therapy has improved life expectancy and quality, limitations include frequent infusions and high costs. Gene therapy is a potential alternative that utilizes an adeno-associated virus (AAV) vector containing the human genetic code for factor 8 (FVIII) that transduces the liver, enabling endogenous production of FVIII. Individuals with preexisting immunity to AAV serotypes may be less likely to benefit from this treatment. OBJECTIVES: This study measured seroprevalence of antibodies to AAV5 and 8 in an UK adult hemophilia A cohort. PATIENTS/METHODS: Patients were recruited from seven hemophilia centres in the UK. Citrated plasma samples from 100 patients were tested for preexisting activities against AAV5 and 8 using AAV transduction inhibition and total antibodies assays. RESULTS: Twent-one percent of patients had antibodies against AAV5 and 23% had antibodies against AAV8. Twenty-five percent and 38% of patients exhibited inhibitors of AAV5 or AAV8 cellular transduction respectively. Overall seroprevalence using either assay against AAV5 was 30% and against AAV8 was 40% in this cohort of hemophilia A patients. Seropositivity for both AAV5 and AAV8 was seen in 24% of participants. CONCLUSIONS: Screening for preexisting immunity may be important in identifying patients most likely to benefit from gene therapy. Clinical studies may be needed to evaluate the impact of preexisting immunity on the safety and efficacy of AAV mediated gene therapy.

8.
Clin Vaccine Immunol ; 23(4): 363-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26888186

ABSTRACT

Prospective studies of antibodies to multiple Epstein-Barr virus (EBV) proteins and EBV neutralizing antibodies in the same individuals before, during, and after primary EBV infection have not been reported. We studied antibody responses to EBV in college students who acquired primary EBV infection during prospective surveillance and correlated the kinetics of antibody response with the severity of disease. Neutralizing antibodies and enzyme-linked immunosorbent assay (ELISA) antibodies to gp350, the major target of neutralizing antibody, reached peak levels at medians of 179 and 333 days after the onset of symptoms of infectious mononucleosis, respectively. No clear correlation was found between the severity of the symptoms of infectious mononucleosis and the peak levels of antibody to individual viral proteins or to neutralizing antibody. In summary, we found that titers of neutralizing antibody and antibodies to multiple EBV proteins increase over many months after primary infection with EBV.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Herpesvirus 4, Human/immunology , Infectious Mononucleosis/immunology , Adaptive Immunity , Enzyme-Linked Immunosorbent Assay , Humans , Infectious Mononucleosis/pathology , Neutralization Tests , Prospective Studies , Severity of Illness Index , Students , Time Factors
9.
Vaccine ; 33(48): 6771-7, 2015 Nov 27.
Article in English | MEDLINE | ID: mdl-26485517

ABSTRACT

Vaccine prophylaxis with EBV glycoprotein 350 (gp350) subunit plus adjuvant has been demonstrated clinically to protect individuals against infectious mononucleosis (IM), but the specifications of the antigen required to elicit this protection has remained largely theoretical. Previous studies have shown that antibodies to gp350 comprise the principle component of EBV-neutralizing sera. Further, a murine monoclonal antibody against gp350 (clone 72A1) is able to prevent infection by the virus both in vitro and in vivo. In the present study, we identify the 72A1 epitope on recombinant gp350 antigen as the site required for binding to CD21 on human B cells. We also identify the need for conformational-dependence of the antigen to generate EBV-neutralizing antibodies in vivo. Further, we have characterized the glycosylation status and antigenicity profiles of both native and denatured CHO-produced soluble gp350 as well as non-glycosylated protein produced in Escherichia coli. Collectively our in vitro and in vivo data demonstrate the requirement for a conformationally accessible 72A1 epitope on gp350 to elicit EBV-neutralizing responses, and establish this as a critical attribute of this vaccine antigen. These data provide direction for commercial vaccine development, as the absence of this epitope on either E. coli-expressed or denatured gp350, may limit production and purification options for the antigen.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Antigens, Viral/immunology , Epitope Mapping , Herpesvirus 4, Human/immunology , Recombinant Proteins/immunology , Animals , Antigens, Viral/chemistry , Antigens, Viral/genetics , Antigens, Viral/metabolism , B-Lymphocytes/immunology , CHO Cells , Cricetulus , Escherichia coli , Glycosylation , Herpesvirus 4, Human/genetics , Protein Binding , Protein Conformation , Rabbits , Receptors, Complement 3d/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
10.
Am J Transl Res ; 7(6): 1181-8, 2015.
Article in English | MEDLINE | ID: mdl-26279761

ABSTRACT

Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS.

11.
Int J Cancer ; 137(3): 710-20, 2015 Aug 01.
Article in English | MEDLINE | ID: mdl-25556716

ABSTRACT

CD98 is expressed on several tissue types and specifically upregulated on fast-cycling cells undergoing clonal expansion. Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia) overexpress CD98. We have identified a CD98-specific mouse monoclonal antibody that exhibits potent preclinical antitumor activity against established lymphoma tumor xenografts. Additionally, the humanized antibody designated IGN523 demonstrated robust tumor growth inhibition in leukemic cell-line derived xenograft models and was as efficacious as standard of care carboplatin in patient-derived nonsmall lung cancer xenografts. In vitro studies revealed that IGN523 elicited strong ADCC activity, induced lysosomal membrane permeabilization and inhibited essential amino acid transport function, ultimately resulting in caspase-3 and -7-mediated apoptosis of tumor cells. IGN523 is currently being evaluated in a Phase I clinical trial for acute myeloid leukemia (NCT02040506). Furthermore, preclinical data support the therapeutic potential of IGN523 in solid tumors.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antineoplastic Agents/pharmacology , Fusion Regulatory Protein-1/antagonists & inhibitors , Amino Acids/metabolism , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/immunology , Antibodies, Monoclonal, Humanized/pharmacology , Antibody-Dependent Cell Cytotoxicity/immunology , Antineoplastic Agents/administration & dosage , Biological Transport , Caspases/metabolism , Cell Line, Tumor , Cell Membrane Permeability , Complement System Proteins/immunology , Cytotoxicity, Immunologic , Disease Models, Animal , Drug Evaluation, Preclinical , Female , Humans , Lysosomes/metabolism , Mice , Models, Biological , Protein Binding , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
12.
J Virol ; 87(20): 11107-20, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23926341

ABSTRACT

Human cytomegalovirus (HCMV), a betaherpesvirus, can cause severe disease in immunosuppressed patients and following congenital infection. A vaccine that induces both humoral and cellular immunity may be required to prevent congenital infection. Dense bodies (DBs) are complex, noninfectious particles produced by HCMV-infected cells and may represent a vaccine option. As knowledge of the antigenicity and immunogenicity of DB is incomplete, we explored characterization methods and defined DB production methods, followed by systematic evaluation of neutralization and cell-mediated immune responses to the DB material in BALB/c mice. DBs purified from Towne-infected cultures treated with the viral terminase inhibitor 2-bromo-5,6-dichloro-1-beta-d-ribofuranosyl benzimidazole riboside (BDCRB) were characterized by nanoparticle tracking analysis (NTA), two-dimensional fluorescence difference gel electrophoresis (2D-DIGE), immunoblotting, quantitative enzyme-linked immunosorbent assay, and other methods. The humoral and cellular immune responses to DBs were compared to the immunogenicity of glycoprotein B (gB) administered with the adjuvant AddaVax (gB/AddaVax). DBs induced neutralizing antibodies that prevented viral infection of cultured fibroblasts and epithelial cells and robust cell-mediated immune responses to multiple viral proteins, including pp65, gB, and UL48. In contrast, gB/AddaVax failed to induce neutralizing antibodies that prevented infection of epithelial cells, highlighting a critical difference in the humoral responses induced by these vaccine candidates. Our data advance the potential for the DB vaccine approach, demonstrate important immunogenicity properties, and strongly support the further evaluation of DBs as a CMV vaccine candidate.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Cytomegalovirus Vaccines/immunology , Cytomegalovirus/immunology , Epithelial Cells/virology , Fibroblasts/virology , Immunity, Cellular , Animals , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Cytomegalovirus Vaccines/administration & dosage , Cytomegalovirus Vaccines/isolation & purification , Epithelial Cells/immunology , Female , Fibroblasts/immunology , Mice , Mice, Inbred BALB C
13.
Clin Cancer Res ; 18(12): 3250-60, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22553345

ABSTRACT

PURPOSE: Prostate cancer is detected with increasing frequency but has a highly variable natural history and prognosis and active surveillance of men with low-risk prostate cancer would benefit greatly from minimally invasive methods to identify progression. We describe here two novel in vivo metrics of cell proliferation in men with prostate neoplasia. EXPERIMENTAL DESIGN: Three groups of men drank heavy water, a nonradioactive, stable isotopic tracer for 14 to 28 days: (i) healthy men, (ii) men scheduled for transrectal core needle biopsy, and (iii) men scheduled for radical prostatectomy. Prostate epithelial cells (PEC) were isolated from ejaculated seminal fluid in all subjects. Histologically graded lesions were microdissected from tissue slides obtained from subjects undergoing surgery and proliferation rates were measured from isolated cells via mass spectrometry. RESULTS: Proliferation rates of seminal PEC in healthy men (0.10%-0.27%/d) were stable on repeat sampling. Rates above 0.34%/d were seen only in patients with cancer where rates increased progressively from normal tissue through benign prostate hyperplasia, prostate intraepithelial neoplasia, and tumor grades III and IV in all subjects. Seminal PEC kinetics correlated highly with the most proliferative microdissected region in each subject (r(2) = 0.94). CONCLUSIONS: Prostate cell proliferation can be measured in vivo from microdissected histopathology sections or noninvasively from seminal fluid where the latter reflects the most proliferative region of the gland. This approach may allow monitoring of progression in men with low-risk prostate cancer.


Subject(s)
Cell Proliferation , Prostate/cytology , Prostate/pathology , Prostatic Neoplasms/pathology , Semen/cytology , Adult , Aged , Cell Separation , Deuterium Oxide , Epithelial Cells/cytology , Epithelial Cells/metabolism , Humans , Ki-67 Antigen/analysis , Male , Middle Aged , Neoplasm Grading , Prostate/metabolism , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Prostatic Intraepithelial Neoplasia/metabolism , Prostatic Intraepithelial Neoplasia/pathology , Prostatic Neoplasms/metabolism
14.
Mol Med ; 17(11-12): 1374-82, 2011.
Article in English | MEDLINE | ID: mdl-21968788

ABSTRACT

The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth of minor subclones with more dangerous genomic abnormalities or with self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured B-cell kinetics in vivo by quantifying deuterium ((2)H)-labeled cells as an indicator of a cell that had divided. Separating CLL clones on the basis of reciprocal densities of chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster designation 5 (CD5) revealed that the CXCR4(dim)CD5(bright) (proliferative) fraction contained more (2)H-labeled DNA and hence divided cells than the CXCR4(bright)CD5(dim) (resting) fraction. This enrichment was confirmed by the relative expression of two cell cycle-associated molecules in the same fractions, Ki-67 and minichromosome maintenance protein 6 (MCM6). Comparisons of global gene expression between the CXCR4(dim)CD5(bright) and CXCR4(bright)CD5(dim) fractions indicated higher levels of pro-proliferation and antiapoptotic genes and genes involved in oxidative injury in the proliferative fraction. An extended immunophenotype was also defined, providing a wider range of surface molecules characteristic of each fraction. These intraclonal analyses suggest a model of CLL cell biology in which the leukemic clone contains a spectrum of cells from the proliferative fraction, enriched in recently divided robust cells that are lymphoid tissue emigrants, to the resting fraction enriched in older, less vital cells that need to immigrate to lymphoid tissue or die. The model also suggests several targets preferentially expressed in the two populations amenable for therapeutic attack. Finally, the study lays the groundwork for future analyses that might provide a more robust understanding of the development and clonal evolution of this currently incurable disease.


Subject(s)
Cell Division , Cellular Senescence , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , CD5 Antigens/metabolism , Cell Compartmentation , Cell Proliferation , Clone Cells , Gene Expression Profiling , Gene Expression Regulation, Leukemic , Genes, Neoplasm/genetics , Humans , Immunophenotyping , Kinetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Models, Biological , Real-Time Polymerase Chain Reaction , Receptors, CXCR4/metabolism , Reproducibility of Results , Subcellular Fractions/metabolism
15.
Sci Total Environ ; 408(24): 6108-16, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20888618

ABSTRACT

Groundwater vulnerability assessment has been an increasingly important environment management tool. The existing vulnerability assessment approaches are mostly index systems which have significant disadvantages. There need to be some quantitative studies on vulnerability indicators based on objective physical process study. In this study, we tried to do vulnerability assessment in Huangshuihe catchment in Shandong province of China using both contaminant transport simulations and index system approach. Transit time of 75% of hypothetical injected contaminant concentration was considered as the vulnerability indicator. First, we collected the field data of the Huangshuihe catchment and the catchment was divided into 34 sub areas that can each be treated as a transport sub model. Next, we constructed a Hydrus1D transport model of Huangshuihe catchment. Different sub areas had different input values. Thirdly, we used Monte-Carlo simulation to improve the collected data and did vulnerability assessment using the statistics of the contaminant transit time as a vulnerability indicator. Finally, to compare with the assessment result by transport simulation, we applied two index systems to Huangshuihe catchment. The first was DRASTIC system, and the other was a system we tentatively constructed examining the relationships between the transit time and the input parameters by simply changing the input values. The result of comparisons between the two index systems and transport simulation approach suggested partial validation to DRASTIC, and the construction of the new tentative index system was an attempt of building up index approaches based on physical process simulation.


Subject(s)
Environmental Monitoring/methods , Fresh Water/chemistry , Models, Chemical , Water Pollutants/analysis , Water Supply/analysis , China , Soil/analysis , Water Pollutants/chemistry , Water Pollution/statistics & numerical data
16.
Leuk Res ; 34(6): 809-15, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19854509

ABSTRACT

BACKGROUND: Heavy water ((2)H(2)O) labelling of DNA enables the measurement of low-level cell proliferation in vivo, using gas chromatography/pyrolysis isotope ratio mass spectrometry (GC/P/IRMS), but the methodology has been too complex for widespread use. Here, we report a simplified method for measuring proliferation of malignant B cells in patients with chronic lymphocytic leukemia (CLL). DESIGN AND METHODS: Patients were labelled with (2)H(2)O for 6 weeks; blood samples were obtained at 0, 3, and 6 weeks during (2)H(2)O labelling and 9, 12, and 16 weeks thereafter. Bone marrow was sampled at week 6. Phlebotomy was performed at multiple, non-research clinical sites. CLL cells were isolated in a central laboratory, using a novel RosetteSep-based method; DNA labelling was analyzed by GC/P/IRMS. RESULTS: In 26 of 29 patients, CLL cell isolation resulted in > or =95% purity for malignant CD5+ B cells; in one patient, malignant cells expressed marginal levels of CD5, and in two others, further sorting of CD5hi malignant cells was required. Cell yields correlated with white blood cell counts and exceeded GC/P/IRMS requirements ( approximately 10(7) cells) >98% of the time; high-quality DNA labelling data were obtained. RosetteSep isolation achieved adequate CLL cell purity from bone marrow in only 64% of samples, but greatly reduced subsequent sort time for impure samples. CONCLUSION: This method enables clinical studies of CLL cell proliferation outside of research settings, using a shorter (2)H(2)O intake protocol, a minimal sampling protocol, and centralised sample processing. The CLL cell isolation protocol may also prove useful in other applications. (clinicaltrials.gov identifier: NCT00481858).


Subject(s)
B-Lymphocytes/pathology , Cell Proliferation , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Adult , Aged , Blood Specimen Collection/methods , Blood Specimen Collection/standards , Bone Marrow Cells/pathology , Cell Separation/methods , Clinical Trials as Topic/methods , Cytodiagnosis/methods , DNA/analysis , Deuterium Oxide/chemistry , Efficiency , Female , Flow Cytometry/methods , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Male , Middle Aged , Multicenter Studies as Topic/methods
17.
Int J Nanomanuf ; 3(4): 351-367, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19966945

ABSTRACT

Statistical design of experiments is widely used among scientists and engineers to understand influential factors in a laboratory or manufacturing process. One of the underlying principles of using the statistical design of experiments method is randomisation, each run of experimental settings will be determined completely unsystematically. In practice, especially in a complicated process that consists of multiple stages, randomisation may pose too high a burden on time and cost.In this study, the multistage fraction factorial split plot design is proposed for green yield improvement in a lost mould rapid infiltration process that has been developed to fabricate zirconia ceramic parts. This design allows a relaxation of the randomisation principle so that certain experimental runs can be carried out in convenient groups. The results indicate that the type of immersion chemical and mould coating play a role in improving process yield. Additionally, the results suggest that a mould infiltration machine should be used to improve the reproducibility of the process.

18.
Blood ; 114(23): 4832-42, 2009 Nov 26.
Article in English | MEDLINE | ID: mdl-19789386

ABSTRACT

Clonal evolution and outgrowth of cellular variants with additional chromosomal abnormalities are major causes of disease progression in chronic lymphocytic leukemia (CLL). Because new DNA lesions occur during S phase, proliferating cells are at the core of this problem. In this study, we used in vivo deuterium ((2)H) labeling of CLL cells to better understand the phenotype of proliferating cells in 13 leukemic clones. In each case, there was heterogeneity in cellular proliferation, with a higher fraction of newly produced CD38+ cells compared with CD38- counterparts. On average, there were 2-fold higher percentages of newly born cells in the CD38+ fraction than in CD38- cells; when analyzed on an individual patient basis, CD38+ (2)H-labeled cells ranged from 6.6% to 73%. Based on distinct kinetic patterns, interclonal heterogeneity was also observed. Specifically, 4 patients exhibited a delayed appearance of newly produced CD38+ cells in the blood, higher leukemic cell CXC chemokine receptor 4 (CXCR4) levels, and increased risk for lymphoid organ infiltration and poor outcome. Our data refine the proliferative compartment in CLL based on CD38 expression and suggest a relationship between in vivo kinetics, expression of a protein involved in CLL cell retention and trafficking to solid tissues, and clinical outcome.


Subject(s)
B-Lymphocytes/cytology , Clone Cells/cytology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Neoplastic Stem Cells/cytology , ADP-ribosyl Cyclase 1/analysis , Antigens, CD19/analysis , CD5 Antigens/analysis , Cell Division , Chemotaxis, Leukocyte , Chromosome Aberrations , DNA Replication , DNA, Neoplasm/metabolism , Deuterium/analysis , Disease Progression , Humans , Immunophenotyping , Ki-67 Antigen/analysis , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Leukemic Infiltration/pathology , Membrane Glycoproteins/analysis , Receptors, CXCR4/analysis , Telomere/ultrastructure , ZAP-70 Protein-Tyrosine Kinase/analysis
19.
J Am Ceram Soc ; 92(Suppl 1): S70-S78, 2009.
Article in English | MEDLINE | ID: mdl-19809594

ABSTRACT

Iterative process improvements have been used to eliminate strength-limiting geometric flaws in mesoscale bend bars composed of yttria-tetragonal zirconia polycrystals (Y-TZP). These improvements led to large quantities of high bend strength material. The metrology of Y-TZP mesoscale bend bars produced using a novel lost mold-rapid infiltration-forming process (LM-RIF) is characterized over several process improvements. These improvements eliminate trapezoidal cross sections in the parts, reduce concave upper surfaces in cross section, and minimize warping along the long axis of 332 x 26 x 17 mum mesoscale bend bars. The trapezoidal cross sections of earlier, first-generation parts were due to the absorption of high-energy ultraviolet (UV) light during the photolithographic mold-forming process, which produced nonvertical mold walls that the parts mirrored. The concave upper surfaces in cross section were eliminated by implementing a RIF-buffing process. Warping during sintering was attributed to impurities in the substrate, which creates localized grain growth and warping as the tetragonal phase becomes destabilized. Precision in the part dimensions is demonstrated using optical profilometry on bend bars and a triangular test component. The bend bar dimensions have a 95% confidence interval of < +/-1 mum, and the tip radius of the triangular test component is 3 mum, consistent with the UV-photolithographic process used to form the mold cavities. The average bend strength of the mesoscale Y-TZP bend exceeds 2 GPa with a Weibull modulus equal to 6.3.

20.
J Am Ceram Soc ; 92(Suppl 1): S63-S69, 2009.
Article in English | MEDLINE | ID: mdl-19809595

ABSTRACT

Free-standing mesoscale (340 mum x 30 mum x 20 mum) bend bars with an aspect ratio over 15:1 and an edge resolution as fine as a single grain diameter ( approximately 400 nm) have been fabricated in large numbers on refractory ceramic substrates by combining a novel powder processing approach with photoresist molds and an innovative lost-mold thermal process. The colloid and interfacial chemistry of the nanoscale zirconia particulates has been modeled and used to prepare highly concentrated suspensions. Engineering solutions to challenges in mold fabrication and casting have yielded free-standing, crack-free parts. Molds are fabricated using high-aspect-ratio photoresist on ceramic substrates. Green parts are formed using a rapid infiltration method that exploits the shear thinning behavior of the highly concentrated ceramic suspension in combination with gelcasting. The mold is thermally decomposed and the parts are sintered in place on the ceramic substrate. Chemically aided attrition milling disperses and concentrates the as-received 3Y-TZP powder to produce a dense, fine-grained sintered microstructure. Initial three-point bend strength data are comparable to that of conventional zirconia; however, geometric irregularities (e.g., trapezoidal cross sections) are present in this first generation and are discussed with respect to the distribution of bend strength.

SELECTION OF CITATIONS
SEARCH DETAIL
...